<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Couturaud, Francis</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Benefit of Extended Anticoagulation After Unprovoked PE Lost After Treatment Discontinuation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">After a first episode of unprovoked pulmonary embolism initially treated during 6 months, extending anticoagulant therapy with warfarin for an additional 18 months significantly reduces the risk of recurrent venous thromboembolism. However, by 2 years after therapy is discontinued, the risk of recurrent thrombolic events is no different between the warfarin treatment group and the placebo group.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>